Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amryt Pharma Plc ADR
(NQ:
AMYT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 11, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
14.63 (8)
Ask (Size)
14.90 (1)
Prev. Close
14.70
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
April 12, 2023
From
Amryt Pharma plc
Via
GlobeNewswire
High Court of Justice of England and Wales Sanctions Scheme of Arrangement
April 03, 2023
From
Amryt Pharma plc
Via
GlobeNewswire
Performance
More News
Read More
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
March 22, 2023
From
Amryt Pharma plc
Via
GlobeNewswire
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
March 14, 2023
Via
Benzinga
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders
February 27, 2023
From
Halper Sadeh LLC
Via
Business Wire
Why Shares of Amryt Pharma Jumped This Week
January 12, 2023
Via
The Motley Fool
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT
February 24, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023
February 16, 2023
From
Amryt Pharma plc
Via
GlobeNewswire
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT
January 10, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
January 18, 2023
Via
Benzinga
S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher
January 09, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 10, 2023
January 10, 2023
Via
Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 09, 2023
Via
Benzinga
Nasdaq Surges Over 200 Points; Crude Oil Rises 2%
January 09, 2023
Via
Benzinga
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
January 09, 2023
Via
Benzinga
US Stocks Open Higher; Dow Rises 150 Points
January 09, 2023
Via
Benzinga
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders
January 09, 2023
From
Halper Sadeh LLC
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 9, 2023
January 09, 2023
Via
Benzinga
Adobe To Rally 25%? Here Are 10 Other Analyst Forecasts For Monday
January 09, 2023
Via
Benzinga
Italian Privately Held Chiesi Farmaceutici To Acquire Amryt Pharma For $1.25B
January 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 09, 2023
Via
Benzinga
Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
January 09, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
January 09, 2023
Via
InvestorPlace
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
January 08, 2023
From
Amryt Pharma plc
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.